[
  {
    "ts": null,
    "headline": "AbbVie: Plenty Of Positives",
    "summary": "AbbVieÂ stock has had a good August, with double digit MoM gains after seeing weakness for six months. Read the latest analysis on AbbVie stock here.",
    "url": "https://finnhub.io/api/news?id=474a24cfcb4a19ff92f56a67018765af7b2ad95010e4861e267195e640121586",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756214665,
      "headline": "AbbVie: Plenty Of Positives",
      "id": 136527016,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2175801616/image_2175801616.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "AbbVieÂ stock has had a good August, with double digit MoM gains after seeing weakness for six months. Read the latest analysis on AbbVie stock here.",
      "url": "https://finnhub.io/api/news?id=474a24cfcb4a19ff92f56a67018765af7b2ad95010e4861e267195e640121586"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie’s (ABBV) Fell in Line with the Broader Biopharmaceutical Industry",
    "summary": "Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Growth & Income Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. The stock market experienced another period of volatility in the second quarter. As of April 8, the S&P 500 Index had declined more than 11% for the quarter […]",
    "url": "https://finnhub.io/api/news?id=9d2be1582cee3c924b2510bf9e0e51e04ba76fd8dc9f62dbdb4b5ec0febf8e92",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756213559,
      "headline": "AbbVie’s (ABBV) Fell in Line with the Broader Biopharmaceutical Industry",
      "id": 136525661,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Growth & Income Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. The stock market experienced another period of volatility in the second quarter. As of April 8, the S&P 500 Index had declined more than 11% for the quarter […]",
      "url": "https://finnhub.io/api/news?id=9d2be1582cee3c924b2510bf9e0e51e04ba76fd8dc9f62dbdb4b5ec0febf8e92"
    }
  },
  {
    "ts": null,
    "headline": "ABBV Buys Rights to Bretisilocin, a Novel Psychedelic for Depression",
    "summary": "AbbVie is acquiring Gilgamesh's lead psychedelic drug bretisilocin for up to $1.2B, aiming to expand its depression treatment pipeline",
    "url": "https://finnhub.io/api/news?id=fa42595c1177faf797db732ed7f6e1b1b7467bbf223251dfe67cc5f10483f65a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756210080,
      "headline": "ABBV Buys Rights to Bretisilocin, a Novel Psychedelic for Depression",
      "id": 136525164,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie is acquiring Gilgamesh's lead psychedelic drug bretisilocin for up to $1.2B, aiming to expand its depression treatment pipeline",
      "url": "https://finnhub.io/api/news?id=fa42595c1177faf797db732ed7f6e1b1b7467bbf223251dfe67cc5f10483f65a"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie agrees to acquire Gilgamesh’s bretisilocin for $1.2bn",
    "summary": "Bretisilocin, a 5-HT2A receptor agonist and 5-HT releaser, has been designed to reduce the duration of psychoactive experience.",
    "url": "https://finnhub.io/api/news?id=ae602edd94a8af6f3782ab86410572cd88d915f4341ac96c423b11e620146eea",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756207353,
      "headline": "AbbVie agrees to acquire Gilgamesh’s bretisilocin for $1.2bn",
      "id": 136525663,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Bretisilocin, a 5-HT2A receptor agonist and 5-HT releaser, has been designed to reduce the duration of psychoactive experience.",
      "url": "https://finnhub.io/api/news?id=ae602edd94a8af6f3782ab86410572cd88d915f4341ac96c423b11e620146eea"
    }
  },
  {
    "ts": null,
    "headline": "Controlled Release Drug Delivery Market and Clinical Pipeline Report: A $90 Billion Opportunity in Controlled Release Drug Delivery by 2030",
    "summary": "The controlled release drug delivery market offers substantial growth opportunities driven by increasing demand for improved therapeutic regimens for chronic conditions like cancer and neurological disorders. Innovations by companies like AbbVie and AstraZeneca, alongside emerging startups, promise advancements in targeted, patient-friendly delivery systems.Dublin, Aug. 26, 2025 (GLOBE NEWSWIRE) -- The \"Global Controlled Release Drug Delivery Market, Drug Dosage, Price and Clinical Pipeline Insi",
    "url": "https://finnhub.io/api/news?id=3ebb564281b3f4a887f8ebbc7d4b72b0fd11495bc4c1158742c26c4a6d66be41",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756195800,
      "headline": "Controlled Release Drug Delivery Market and Clinical Pipeline Report: A $90 Billion Opportunity in Controlled Release Drug Delivery by 2030",
      "id": 136523909,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "The controlled release drug delivery market offers substantial growth opportunities driven by increasing demand for improved therapeutic regimens for chronic conditions like cancer and neurological disorders. Innovations by companies like AbbVie and AstraZeneca, alongside emerging startups, promise advancements in targeted, patient-friendly delivery systems.Dublin, Aug. 26, 2025 (GLOBE NEWSWIRE) -- The \"Global Controlled Release Drug Delivery Market, Drug Dosage, Price and Clinical Pipeline Insi",
      "url": "https://finnhub.io/api/news?id=3ebb564281b3f4a887f8ebbc7d4b72b0fd11495bc4c1158742c26c4a6d66be41"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie dives back into the neuro pool with a $1.2B psychedelics play",
    "summary": "Following a major clinical failure last year, AbbVie’s purchase of a psychedelic depression treatment has the potential to revive a touch-and-go market.",
    "url": "https://finnhub.io/api/news?id=fe04739d963291b4edfd336939ba366d9870f3bbe5bd6fc61f0ef92caf6e8065",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756195200,
      "headline": "AbbVie dives back into the neuro pool with a $1.2B psychedelics play",
      "id": 136525664,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Following a major clinical failure last year, AbbVie’s purchase of a psychedelic depression treatment has the potential to revive a touch-and-go market.",
      "url": "https://finnhub.io/api/news?id=fe04739d963291b4edfd336939ba366d9870f3bbe5bd6fc61f0ef92caf6e8065"
    }
  },
  {
    "ts": null,
    "headline": "How To Put $100 In Your Retirement Fund Each Month With AbbVie Stock",
    "summary": "AbbVie Inc. (NYSE:ABBV) is a global biopharmaceutical company that discovers, develops, and delivers innovative medicines and solutions for complex health issues in therapeutic areas like immunology, oncology, neuroscience, and eye care. It will ...",
    "url": "https://finnhub.io/api/news?id=632ad15f9746269c7dd9be42dc9c7c751295e99f2a371f26baea2ec18cb5f584",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756173665,
      "headline": "How To Put $100 In Your Retirement Fund Each Month With AbbVie Stock",
      "id": 136523910,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie Inc. (NYSE:ABBV) is a global biopharmaceutical company that discovers, develops, and delivers innovative medicines and solutions for complex health issues in therapeutic areas like immunology, oncology, neuroscience, and eye care. It will ...",
      "url": "https://finnhub.io/api/news?id=632ad15f9746269c7dd9be42dc9c7c751295e99f2a371f26baea2ec18cb5f584"
    }
  }
]